Zenas BioPharma, Inc.

NasdaqGS:ZBIO Stock Report

Market Cap: US$1.6b

Zenas BioPharma Past Earnings Performance

Past criteria checks 0/6

Zenas BioPharma's earnings have been declining at an average annual rate of -63.4%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 100% per year.

Key information

-63.37%

Earnings growth rate

73.97%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-100.00%
Return on equity-126.60%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Apr 30

Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026

Summary Zenas BioPharma, Inc. maintains a Strong Buy rating, driven by obexelimab's positive phase 3 results in IgG4-RD and regulatory filings planned for 2026. ZBIO is advancing obexelimab into the large SLE market, with phase 2 SunStone topline and biomarker data expected in Q4 2026. Pipeline expansion includes ZB014, a half-life extended anti-CD19/FcγRIIb mAb aiming for once-monthly dosing, and CNS-penetrant BTK inhibitor orelabrutinib in phase 3 for MS. ZBIO's cash runway extends into Q2 2027, with potential for further extension into Q4 2027 upon obexelimab approval. Read the full article on Seeking Alpha
Analysis Article • Dec 24

Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher

Zenas BioPharma, Inc. ( NASDAQ:ZBIO ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Jul 11

Here's Why We're Watching Zenas BioPharma's (NASDAQ:ZBIO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Mar 13

Is Zenas BioPharma (NASDAQ:ZBIO) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Oct 22

Zenas Bio: Recent IPO With Late-Stage Candidate

Summary Zenas BioPharma, Inc.'s obexelimab targets CD19 and FcγRIIb to modulate B-cells, aiming to treat multiple autoimmune diseases with fewer side effects. Phase 2 data for obexelimab in IgG4-RD showed strong clinical improvement and a high complete remission rate, with manageable adverse events. Zenas has a solid financial position post-IPO, with recent funding and a collaboration with Bristol-Myers Squibb, ensuring a decent cash runway. Despite the promising late-stage asset, I remain cautious due to the uncertainties surrounding recent IPOs and limited financial data. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Zenas BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ZBIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-425580
31 Dec 2510-378530
30 Sep 2515-190490
30 Jun 2515-177430
31 Mar 2515-163370
31 Dec 245-157300
30 Sep 240-129230
30 Jun 2450-87200
31 Mar 2450-46180
31 Dec 2350-37170
30 Sep 2350-32160

Quality Earnings: ZBIO is currently unprofitable.

Growing Profit Margin: ZBIO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ZBIO is unprofitable, and losses have increased over the past 5 years at a rate of 63.4% per year.

Accelerating Growth: Unable to compare ZBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: ZBIO has a negative Return on Equity (-126.6%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 02:10
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zenas BioPharma, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yigal NochomovitzCitigroup Inc
Cory KasimovEvercore ISI
Yatin SunejaGuggenheim Securities, LLC